HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Accepteret manuskript, 215 KB, PDF-dokument
Objectives: Although direct-acting antivirals (DAAs) can clear HCV in nearly all HIV/HCV-coinfected individuals, high rates of reinfection may hamper efforts to eliminate HCV in this population. We investigated reinfection after sustained virological response (SVR) in HIV/HCV-coinfected individuals in Europe. Methods: Factors associated with odds of reinfection by 2 years after SVR in EuroSIDA participants with one or more HCV-RNA test and 2 years follow-up were assessed using logistic regression. Results: Overall, 1022 individuals were included. The median age was 50 (interquartile range: 43–54 years), and most were male (78%), injection drug users (52%), and received interferon (IFN)-free DAAs (62%). By 24 months, 75 [7.3%, 95% confidence interval (CI): 5.7–8.9%] individuals were reinfected. Among individuals treated prior to 2014, 16.1% were reinfected compared with 4.2% and 8.3%, respectively, among those treated during or after 2014 with IFN-free and IFN-based therapy. After adjustment, individuals who had started treatment during or after 2014 with IFN-free or IFN-based therapy had significantly lower odds of reinfection (adjusted odds ratio = 0.21, 95% CI: 0.11–0.38; 0.43, 95% CI: 0.22–0.83) compared with those who had received therapy before 2014. There were no significant differences in odds of reinfection according to age, gender, European region, HIV transmission risk group or liver fibrosis. Conclusions: Among HIV/HCV-coinfected individuals in Europe, 7.3% were reinfected with HCV within 24 months of achieving SVR, with evidence suggesting that this is decreasing over time and with use of newer HCV regimens. Harm reduction to reduce reinfection and surveillance to detect early reinfection with an offer of treatment are essential to eliminate HCV.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | HIV Medicine |
| Vol/bind | 23 |
| Udgave nummer | 6 |
| Sider (fra-til) | 684-692 |
| Antal sider | 9 |
| ISSN | 1464-2662 |
| DOI | |
| Status | Udgivet - 2022 |
Bibliografisk note
Funding Information:
TB reports grants from Novo Nordisk Foundation, grants from Simonsen Foundation, grants and personal fees from GSK, grants and personal fees from Pfizer, personal fees from Boehringer Ingelheim, grants and personal fees from Gilead, personal fees from MSD, grants from Lundbeck Foundation, grants from Kai Hansen Foundation, personal fees from Pentabase ApS, and grants from Erik and Susanna Olesen's Charitable Fund, outside the submitted work. JKR reports honoraria, consultancy fees, travel support and/or lecture fees from Abivax, Galapagos, Gilead, Janssen, Merck, Theratechnologies, and ViiV, outside the submitted work. RM reports educational grants, consultancy fees, travel support and/or lecture fees from Abbvie, Johnson and Johnson, MSD, ViiV Healthcare, GlaxoSmithKline, INTEGRATE and WEEPI project grants, outside the submitted work. AM reports honoraria, consultancy fees, travel support and/or lecture fees from Gilead, ViiV and Eiland and Bonnin PC, outside the submitted work. All other authors report no conflicts of interest.
Funding Information:
EuroSIDA was supported by the European Union's Seventh Framework Programme for research, technological development and demonstration under EuroCoord grant agreement no. 260694. Current support includes unrestricted grants by ViiV Healthcare LLC, GlaxoSmithKline R&D Limited, Janssen Scientific Affairs, Janssen R&D, Bristol‐Myers Squibb Company, Merck Sharp & Dohme Corp and Gilead Sciences. The participation of centres from Switzerland was supported by The Swiss National Science Foundation (grant 148522). The study is also supported by a grant (grant no. DNRF126) from the Danish National Research Foundation and by the International Cohort Consortium of Infectious Disease (RESPOND).
Publisher Copyright:
© 2021 British HIV Association.
ID: 329429340